ReviewExpert opinion on drug discovery2015
Drug discovery for alopecia: gone today, hair tomorrow.
Review in Expert opinion on drug discovery, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 117 citations in OpenAlex.
- A Comparative Study on the Application of Robotic Hair Restoration Technology Versus Traditional Follicular Unit Excision in Male Androgenetic Alopecia.Journal of cosmetic dermatology · 2024Trial
- Enhancing hair growth in male androgenetic alopecia by a combination of fractional COLasers in medical science · 2017Trial
- Effective topical delivery of minoxidil via chitosan coated nanocapsules to remodel microenvironment of dermal follicle for hair regeneration.Drug delivery and translational research · 2026Article
- Local Pharmacokinetics and Tolerability of Topically-Applied Bimatoprost to the Scalp of Male Patients With Androgenetic Alopecia.Clinical and translational science · 2026Article
- Dental pulp stem cell exosomes promote angiogenesis via the PI3K/Akt signaling pathway to treat androgenetic alopecia.Stem cell research & therapy · 2026Article
- Technological Advances in Anti-hair Loss and Hair Regrowth Cosmeceuticals: Mechanistic Breakthroughs and Industrial Prospects Driven by Multidisciplinary Collaborative Innovation.Aesthetic plastic surgery · 2025Review
- Recent Advances in Drug Development for Hair Loss.International journal of molecular sciences · 2025Review
- Role of Polyphenols in Dermatological Diseases: Exploring Pharmacotherapeutic Mechanisms and Clinical Implications.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Microneedle-Based Approaches for Skin Disease Treatment.Nano-micro letters · 2025Review
- Decreased expression of cytokeratin 15 and tropoelastin in men with androgenetic alopecia and its relationship with increased expression of p15/p16.Archives of medical science : AMS · 2025Article
- Application of Thulium 1927-nm Laser for Androgenic Alopecia Treatment in Indonesian Patients.Journal of lasers in medical sciences · 2025Article
- The Hormonal Background of Hair Loss in Non-Scarring Alopecias.Biomedicines · 2024Review
- CBD: A Potential Lead against Hair Loss, Alopecia, and its Potential Mechanisms.Current drug discovery technologies · 2024Review
- High-Throughput Screening of 3-Dimensional Co-culture Hair Follicle Mimetic Tissue with an Enhanced Extracellular Matrix for the Screening of Hair Growth-Promoting Compounds.Biomaterials research · 2024Article
- Effects of oxytocin on the hair growth ability of dermal papilla cells.Scientific reports · 2023Article
- Effects of the Complex ofNutrients · 2023Article
- In vitro hair follicle growth model for drug testing.Scientific reports · 2023Article
- The Philippines stingless bee propolis promotes hair growth through activation of Wnt/β-catenin signaling pathway.Experimental animals · 2023Article
- Hydroxychloroquine for granuloma annulare: A case report on secondary hair growth in alopecia universalis.SAGE open medical case reports · 2023Article
- Unrevealing the Potential ofMolecules (Basel, Switzerland) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 2 countries.
Funding
Abstract
introductionHair loss or alopecia affects the majority of the population at some time in their life, and increasingly, sufferers are demanding treatment. Three main types of alopecia (androgenic [AGA], areata [AA] and chemotherapy-induced [CIA]) are very different, and have their own laboratory models and separate drug-discovery efforts. AREAS COVERED: In this article, the authors review the biology of hair, hair follicle (HF) cycling, stem cells and signaling pathways. AGA, due to dihydrotesterone, is treated by 5-α reductase inhibitors, androgen receptor blockers and ATP-sensitive potassium channel-openers. AA, which involves attack by CD8(+)NK group 2D-positive (NKG2D(+)) T cells, is treated with immunosuppressives, biologics and JAK inhibitors. Meanwhile, CIA is treated by apoptosis inhibitors, cytokines and topical immunotherapy. EXPERT OPINION: The desire to treat alopecia with an easy topical preparation is expected to grow with time, particularly with an increasing aging population. The discovery of epidermal stem cells in the HF has given new life to the search for a cure for baldness. Drug discovery efforts are being increasingly centered on these stem cells, boosting the hair cycle and reversing miniaturization of HF. Better understanding of the molecular mechanisms underlying the immune attack in AA will yield new drugs. New discoveries in HF neogenesis and low-level light therapy will undoubtedly have a role to play.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.